Markopoulou K, Dickson D W, McComb R D, Wszolek Z K, Katechalidou L, Avery L, Stansbury M S, Chase B A
Department of Neurology, University of Thessaly Medical School, Papakyriazi 22, Larissa, 41222, Greece.
Acta Neuropathol. 2008 Jul;116(1):25-35. doi: 10.1007/s00401-008-0372-4. Epub 2008 Apr 4.
Individuals with familial Parkinson's disease (PD) due to a monogenic defect can show considerable clinical and neuropathological variability. To identify factors underlying this variability, histopathological analysis was performed in two clinically different A53T alpha-synuclein heterozygotes from Family H, a multigenerational alpha-synuclein A53T kindred. To determine whether additional genetic factors could contribute to phenotypic variability, Family H and another multigenerational A53T kindred were analyzed for parkin polymorphisms. We identified a previously described variant in parkin exon 4 associated with increased PD risk (S167N). The two A53T heterozygotes had markedly different neuropathology and different parkin genotypes: A N167 homozygote had early onset rapidly progressive disease, early dementia, myoclonus and sleep disorder, while a S167 homozygote had late onset, slowly progressive disease and late dementia. Both had brainstem, cortical, and intraneuritic Lewy bodies (LB). The N167 individual had widespread cortical neurofibrillary degeneration, while the S167 individual had only medial temporal lobe neurofibrillary degeneration. The N167 individual had severe neuronal loss in CA2 associated with Lewy neurites (LN), while the S167 individual had severe neuronal loss in CA1 associated with TDP-43 immunoreactive neuronal inclusions. These findings implicate TDP-43 in the pathology of familial PD and suggest that parkin may act as a modifier of the A53T alpha-synuclein phenotype of familial PD. Furthermore, they suggest a mechanism by which a rare genetic variant that is associated with a minor increase of PD risk in the heterozygous state may, in the homozygous state, exacerbate a disease phenotype associated with a highly penetrant dominant allele.
由于单基因缺陷导致的家族性帕金森病(PD)患者可能表现出显著的临床和神经病理学变异性。为了确定这种变异性背后的因素,对来自一个多代α-突触核蛋白A53T家族(家族H)的两名临床症状不同的A53Tα-突触核蛋白杂合子进行了组织病理学分析。为了确定其他遗传因素是否可能导致表型变异性,对家族H和另一个多代A53T家族进行了帕金多态性分析。我们在帕金外显子4中鉴定出一个先前描述的与PD风险增加相关的变体(S167N)。这两名A53T杂合子具有明显不同的神经病理学和不同的帕金基因型:一名N167纯合子患有早发性快速进展性疾病、早期痴呆、肌阵挛和睡眠障碍;而一名S167纯合子患有晚发性、缓慢进展性疾病和晚期痴呆。两人均有脑干、皮质和神经内路易小体(LB)。N167个体有广泛的皮质神经原纤维变性,而S167个体仅在内侧颞叶有神经原纤维变性。N167个体在CA2区有与路易神经突(LN)相关的严重神经元丢失,而S167个体在CA1区有与TDP-43免疫反应性神经元包涵体相关的严重神经元丢失。这些发现表明TDP-43与家族性PD的病理有关,并提示帕金可能作为家族性PD的A53Tα-突触核蛋白表型的修饰因子。此外,它们提示了一种机制,即一种在杂合状态下与PD风险轻微增加相关的罕见遗传变体,在纯合状态下可能会加重与高外显率显性等位基因相关的疾病表型。